Duplicate Serial Numbers in the Specialty Delivery
On Tuesday morning a delivery arrives from a secondary wholesaler your pharmacy has used twice before. It contains 10 cartons of adalimumab 40 mg/0.8 mL prefilled syringes, a high-cost biologic that your pharmacy dispenses under a specialty contract. The packing slip lists the product and lot numbers, but there is no transaction statement in the box and no serialized product data in the wholesaler's portal. Two cartons bear the same serial number. On one carton the tamper-evident seal is broken and the plunger rod looks slightly depressed. The wholesaler's customer service representative says, 'Just scan what you can; the statement will follow, and the seal probably happened in transit. We can credit you if you send it back.' Your pharmacy is an authorized trading partner and is DSCSA-compliant.
1. Is this a suspect product? Identify each fact that triggers suspect-product status under DSCSA.
Read the worked answer
Yes - this is a suspect product. DSCSA defines a suspect product as one for which there is reason to believe it is counterfeit, diverted, stolen, adulterated, or subject to a fraudulent transaction. Each fact contributes:
- No transaction statement and no serialized product data: the pharmacy cannot verify the transaction information/statement required at transfer.
- Duplicate serial numbers: a product identifier must be unique; duplication suggests counterfeiting or repackaging.
- Broken tamper-evident seal and depressed plunger: possible adulteration, sterility compromise, or temperature damage.
- A secondary wholesaler that cannot produce the documentation and tells you to 'scan what you can': a noncompliance signal.
- The offer of credit for return is irrelevant to the legal status of the product.
2. What must you do with the product, the wholesaler, and the FDA, and in what timeframe?
Read the worked answer
Immediate actions:
- Quarantine the cartons in a locked, labeled area; do not dispense, distribute, or destroy them.
- Do not return the product to the wholesaler yet; returning a suspect product without investigation can put it back into the supply chain.
- Investigate: request the full transaction statement, transaction history, and serialized data from the wholesaler; verify the wholesaler's license and status as an authorized trading partner.
- If the product cannot be cleared, notify FDA using Form 3911 (Drug Notification Form) within 24 hours of determining it is illegitimate, and notify immediate trading partners who may have received the product.
- Document everything - who, what, when, lot and serial numbers, communications - and retain records.
- Notify your compliance officer and, if required by state law, the board of pharmacy.
3. Can you accept the wholesaler's 'credit and send it back' offer and close the matter?
Read the worked answer
No. Do not accept the credit as a reason to skip the investigation. If the product is determined not to be suspect or illegitimate, it may be returned to the authorized trading partner with documentation. If it is illegitimate or remains suspect and cannot be cleared, follow FDA instructions; do not return it to the supply chain or destroy it without authorization. The credit offer is a business matter, not a legal clearance. Closing the matter without documentation would leave the pharmacy unable to show that it handled a suspect product as DSCSA requires.